Eli Lilly and Company (NYSE:LLY) Shares Sold by Pittenger & Anderson Inc.

Pittenger & Anderson Inc. reduced its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 39.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 542 shares of the company's stock after selling 351 shares during the period. Pittenger & Anderson Inc.'s holdings in Eli Lilly and Company were worth $448,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Rainey & Randall Wealth Advisors Inc. acquired a new stake in Eli Lilly and Company in the first quarter valued at $336,000. Iron Horse Wealth Management LLC grew its holdings in Eli Lilly and Company by 100.0% in the 1st quarter. Iron Horse Wealth Management LLC now owns 66 shares of the company's stock valued at $55,000 after buying an additional 33 shares during the period. Westmount Partners LLC grew its holdings in Eli Lilly and Company by 3.6% in the 1st quarter. Westmount Partners LLC now owns 2,144 shares of the company's stock valued at $1,771,000 after buying an additional 75 shares during the period. Mason Investment Advisory Services Inc. grew its holdings in shares of Eli Lilly and Company by 22.2% during the 1st quarter. Mason Investment Advisory Services Inc. now owns 330 shares of the company's stock worth $273,000 after purchasing an additional 60 shares during the period. Finally, Stephens Inc. AR grew its holdings in shares of Eli Lilly and Company by 3.4% during the 1st quarter. Stephens Inc. AR now owns 36,485 shares of the company's stock worth $30,133,000 after purchasing an additional 1,197 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. UBS Group decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price target for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Guggenheim upped their price target on Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a report on Friday. Finally, Morgan Stanley restated an "overweight" rating and issued a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $1,012.56.

Eli Lilly and Company Stock Performance

LLY stock opened at $793.34 on Monday. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The firm has a market cap of $751.88 billion, a P/E ratio of 64.55, a P/E/G ratio of 1.16 and a beta of 0.40. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The stock's 50 day simple moving average is $766.39 and its 200 day simple moving average is $800.06.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business's revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.58 earnings per share. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.76%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.